IYH is trading at $71.67, down 3.00% from the August 21 close amid global risk aversion.
- U.S. futures and technology lower; elevated long-term Treasury yields concern markets after the 30-year yield reached 5.34%.
- No major U.S. economic release is scheduled August 24, 2026; no confirmed healthcare-specific catalyst explains the full decline.
- Constructive headlines included Gilead’s expanded European Trodelvy approval and Johnson & Johnson modestly higher pre-market; coverage cited defensive rotation/recent gains, making the move unusually large, potentially liquidity-driven.